Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
1 Month : From Oct 2019 to Nov 2019
By Colin Kellaher
Johnson & Johnson's (JNJ) Janssen Pharmaceutical Cos. unit on Friday said it received Health Canada approval of the cancer drug Imbruvica in combination with obinutuzumab for treatment-naive patients with active chronic lymphocytic leukemia, or CLL.
Janssen said the indication marks the first approval for a non-chemotherapy combination regimen for treatment-naive patients with CLL, one of the most common types of leukemia in adults.
It also marks the ninth indication for Imbruvica in Canada since its first approval in November 2014, Janssen said.
Imbruvica is commercialized in Canada by Janssen, which jointly develops the drug with AbbVie Inc.'s (ABBV) Pharmacyclics LLC.
Write to Colin Kellaher at email@example.com
(END) Dow Jones Newswires
November 08, 2019 09:02 ET (14:02 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.